Trifluridine/tipiracil Overcomes the Resistance of Human Gastric 5-fluorouracil-refractory Cells with High Thymidylate Synthase Expression

Overview

Journal Oncotarget

Specialty Oncology

Date 2018 Mar 24

PMID 29568368

Citations 15

Authors

Kazuaki Matsuoka

Fumio Nakagawa

Takashi Kobunai

Teiji Takechi

Affiliations

Soon will be listed here.

Abstract

Trifluridine/tipiracil (FTD/TPI or TFTD, also known as TAS-102) is a combination of the antineoplastic thymidine analog, FTD, and thymidine phosphorylase inhibitor, TPI (molar ratio 1:0.5). FTD/TPI was approved in Japan, the United States, and the European Union for the treatment of unresectable advanced or recurrent colorectal cancer. We evaluated the and efficacy and mechanisms of action of FTD and FTD/TPI against 5-fluorouracil (5-FU)-resistant MKN45/5FU, MKN74/5FU, and KATOIII/5FU human gastric cancer cells overexpressing thymidylate synthase (TS) and their respective parent cell lines. MKN45/5FU and KATOIII/5FU cells were not cross-resistant to FTD, whereas MKN45/5FU cells were 3.7-fold more resistant than the parental cells . FTD was also incorporated into genomic DNA in a concentration-dependent manner in 5-FU-resistant and parental cells. Additionally, deoxyuridine monophosphate levels in MKN45/5FU cells after 24-h FTD treatment were 3.0-fold higher than those in parental cells, and FTD treatment for 72 h induced G2/M arrest in MKN45/5FU cells, unlike the S phase arrest in MKN45 cells. Thus, TS-overexpressing MKN45/5FU cells, but not MKN74/5FU and KATOIII/5FU cells, showed partial cross-resistance to FTD. However, FTD/TPI (administered orally twice a day) exhibited antitumor activity to the same extent in MKN45 and MKN45/5FU xenograft mouse models, overcoming cross-resistance to FTD. DNA incorporation rather than TS inhibition seems to be the main action of FTD under these conditions. Thus, FTD/TPI is a promising chemotherapeutic agent against gastric cancers recurring following 5-FU therapy.

Citing Articles

Integrated analysis reveals a novel 5-fluorouracil resistance-based prognostic signature with promising implications for predicting the efficacy of chemotherapy and immunotherapy in patients with colorectal cancer.

Hou Y, Zhang F, Zong J, Li T, Gan W, Lv S Apoptosis. 2024; 29(7-8):1126-1144.

PMID: 38824480 DOI: 10.1007/s10495-024-01981-2.

Synthesis of Fluorinated Nucleosides/Nucleotides and Their Antiviral Properties.

Kothapalli Y, Jones R, Chu C, Singh U Molecules. 2024; 29(10).

PMID: 38792251 PMC: 11124531. DOI: 10.3390/molecules29102390.

A Retrospective Study of Trifluridine/Tipiracil with Fruquintinib in Patients with Chemorefractory Metastatic Colorectal Cancer.

Zou J, Wang Y, Xu J, Li J, Wang T, Zhang Y J Clin Med. 2024; 13(1).

PMID: 38202064 PMC: 10779919. DOI: 10.3390/jcm13010057.

Long-Term Progression-Free Survival of a Pre-Treated Patient with Metastatic Colorectal Cancer Receiving Trifluridine/Tipiracil.

Michl G, Vogt F, Nouriani A, Ladurner R, Kremer M, Reislander T Chemotherapy. 2023; 69(1):27-34.

PMID: 37336201 PMC: 10898807. DOI: 10.1159/000531525.

Lineage of drug discovery research on fluorinated pyrimidines: chronicle of the achievements accomplished by Professor Setsuro Fujii.

Maehara Y, Oki E, Ota M, Harimoto N, Ando K, Nakanishi R Int J Clin Oncol. 2023; 28(5):613-624.

PMID: 36961615 DOI: 10.1007/s10147-023-02326-w.

References

Young J, Yao S, Sun L, Cass C, Baldwin S . Human equilibrative nucleoside transporter (ENT) family of nucleoside and nucleobase transporter proteins. Xenobiotica. 2008; 38(7-8):995-1021. DOI: 10.1080/00498250801927427. View

Overman M, Kopetz S, Varadhachary G, Fukushima M, Kuwata K, Mita A . Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors. Cancer Invest. 2008; 26(8):794-9. DOI: 10.1080/07357900802087242. View

Saotome K, Morita H, Umeda M . Cytotoxicity test with simplified crystal violet staining method using microtitre plates and its application to injection drugs. Toxicol In Vitro. 2010; 3(4):317-21. DOI: 10.1016/0887-2333(89)90039-8. View

Marchal J, Boulaiz H, Suarez I, Saniger E, Campos J, Carrillo E . Growth inhibition, G(1)-arrest, and apoptosis in MCF-7 human breast cancer cells by novel highly lipophilic 5-fluorouracil derivatives. Invest New Drugs. 2004; 22(4):379-89. DOI: 10.1023/B:DRUG.0000036680.52016.5f. View

Tanaka N, Sakamoto K, Okabe H, Fujioka A, Yamamura K, Nakagawa F . Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models. Oncol Rep. 2014; 32(6):2319-26. PMC: 4240496. DOI: 10.3892/or.2014.3487. View

Mayer R, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N . Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015; 372(20):1909-19. DOI: 10.1056/NEJMoa1414325. View

Balin-Gauthier D, Delord J, Rochaix P, Mallard V, Thomas F, Hennebelle I . In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR. Cancer Chemother Pharmacol. 2005; 57(6):709-18. DOI: 10.1007/s00280-005-0123-3. View

Inaba M, Mitsuhashi J, Sawada H, Miike N, Naoe Y, Daimon A . Reduced activity of anabolizing enzymes in 5-fluorouracil-resistant human stomach cancer cells. Jpn J Cancer Res. 1996; 87(2):212-20. PMC: 5921054. DOI: 10.1111/j.1349-7006.1996.tb03161.x. View

Aschele C, Debernardis D, Bandelloni R, Cascinu S, Catalano V, Giordani P . Thymidylate synthase protein expression in colorectal cancer metastases predicts for clinical outcome to leucovorin-modulated bolus or infusional 5-fluorouracil but not methotrexate-modulated bolus 5-fluorouracil. Ann Oncol. 2002; 13(12):1882-92. DOI: 10.1093/annonc/mdf327. View

10.

Doi T, Ohtsu A, Yoshino T, Boku N, Onozawa Y, Fukutomi A . Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours. Br J Cancer. 2012; 107(3):429-34. PMC: 3405214. DOI: 10.1038/bjc.2012.274. View

11.

Fukushima M, Suzuki N, Emura T, Yano S, Kazuno H, Tada Y . Structure and activity of specific inhibitors of thymidine phosphorylase to potentiate the function of antitumor 2'-deoxyribonucleosides. Biochem Pharmacol. 2000; 59(10):1227-36. DOI: 10.1016/s0006-2952(00)00253-7. View

12.

Temmink O, Bijnsdorp I, Prins H, Losekoot N, Adema A, Smid K . Trifluorothymidine resistance is associated with decreased thymidine kinase and equilibrative nucleoside transporter expression or increased secretory phospholipase A2. Mol Cancer Ther. 2010; 9(4):1047-57. DOI: 10.1158/1535-7163.MCT-09-0932. View

13.

Carli D, Honorat M, Cohen S, Megherbi M, Vignal B, Dumontet C . Simultaneous quantification of 5-FU, 5-FUrd, 5-FdUrd, 5-FdUMP, dUMP and TMP in cultured cell models by LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2009; 877(27):2937-44. DOI: 10.1016/j.jchromb.2009.07.004. View

14.

Nakamura A, Nakajima G, Okuyama R, Kuramochi H, Kondoh Y, Kanemura T . Enhancement of 5-fluorouracil-induced cytotoxicity by leucovorin in 5-fluorouracil-resistant gastric cancer cells with upregulated expression of thymidylate synthase. Gastric Cancer. 2013; 17(1):188-95. PMC: 3889291. DOI: 10.1007/s10120-013-0249-7. View

15.

Murakami Y, Kazuno H, Emura T, Tsujimoto H, Suzuki N, Fukushima M . Different mechanisms of acquired resistance to fluorinated pyrimidines in human colorectal cancer cells. Int J Oncol. 2000; 17(2):277-83. DOI: 10.3892/ijo.17.2.277. View

16.

Yoshino T, Mizunuma N, Yamazaki K, Nishina T, Komatsu Y, Baba H . TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol. 2012; 13(10):993-1001. DOI: 10.1016/S1470-2045(12)70345-5. View

17.

DE Angelis P, Svendsrud D, Kravik K, Stokke T . Cellular response to 5-fluorouracil (5-FU) in 5-FU-resistant colon cancer cell lines during treatment and recovery. Mol Cancer. 2006; 5:20. PMC: 1524802. DOI: 10.1186/1476-4598-5-20. View

18.

Fukushima M, Satake H, Uchida J, Shimamoto Y, Kato T, Takechi T . Preclinical antitumor efficacy of S-1: a new oral formulation of 5-fluorouracil on human tumor xenografts. Int J Oncol. 1998; 13(4):693-8. DOI: 10.3892/ijo.13.4.693. View

19.

Temmink O, Hoebe E, Fukushima M, Peters G . Irinotecan-induced cytotoxicity to colon cancer cells in vitro is stimulated by pre-incubation with trifluorothymidine. Eur J Cancer. 2006; 43(1):175-83. DOI: 10.1016/j.ejca.2006.08.022. View

20.

Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K . Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs. 1996; 7(5):548-57. DOI: 10.1097/00001813-199607000-00010. View